News for iBio, Inc. (IBIO)

iBio (IBIO) has commenced a preclinical study for its reengineered antibody, IBIO-610, targeting Activin E. This study aims to assess the pharmacokinetics and p

iBio has initiated a non-human primate study for its Activin E antibody, IBIO-610, targeting obesity. Preclinical studies showed up to 77% fat reduction

iBio nominates IBIO-610 as development candidate for its first-in-class Activin E antibody New study aims to evaluate the half-life of IBIO-610 in obese, elder

We came across a bullish thesis on Merck & Co., Inc. (MRK) on Value Investing Subreddit Page by CompanyCharts. In this article, we will summarize the bulls’ thesis on MRK. Merck & Co., Inc. (MRK)’s share was trading at $77.23 as of May 19th. MRK’s trailing and forward P/E were 11.23 and 8.64 respectively according to Yahoo […]

In recent developments, Chardan Capital's analyst, Keay Nakae, has maintained a Buy rating on iBio (IBIO) as of May 6, 2025. The decision to uphold this rating

iBio (IBIO) has received a reaffirmation of its Buy rating from Chardan Capital, as indicated in the latest analyst report dated May 5, 2025. The analyst behind

iBio (IBIO) has revealed encouraging preclinical results for its pioneering Activin E antibody, initially introduced in January. The findings from a recent four

Activin E antibody demonstrates significant decrease in fat in obese mice by reducing visceral fat depots, which are strongly linked to increased risk of cardio

**media[612719]**

iBio (IBIO) raises $6.2 million through warrant inducement transaction. Existing warrant holders purchase 5.6 million shares at $1.11 per share. Char

SAN DIEGO, Feb. 19, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO), an AI-driven innovator of precision antibody therapies, today announced that iBio's common stock has been approved for listing on the Nasdaq Capital

We recently published a list of 10 Stocks Insiders Are Buying This Year. In this article, we are going to take a look at where Ibio, Inc.

On December 31, 2024, ADAR1 Capital Management, LLC (Trades, Portfolio) executed a notable transaction involving iBio Inc. The firm increased its stake in the b

Opaleye Management Inc. (Trades, Portfolio) recently executed a significant stock transaction, acquiring an additional 375,000 shares of iBio Inc. on December 3

**media[537048]**

Insider Trading Roundup: Monday's Top Buys and Sells in US Stocks

**media[507928]**

On December 31, 2024, SABBY MANAGEMENT, LLC (Trades, Portfolio) executed a strategic acquisition of 19,250 shares in iBio Inc, a biotechnology company, at a pri

**media[504088]**